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Abstract
Disorders of thyroid function are among the commonest referrals to endocrinology. While interpretation of thyroid function
testing is usually straightforward, accurate interpretation becomes significantly more challenging when the parameters do not
behave as would be expected in normal negative feedback. In such cases, uncertainty regarding further investigation and
management arises. An important abnormal pattern encountered in clinical practice is that of high normal or raised free thyroxine
(fT4) with inappropriately non-suppressed or elevated thyroid-stimulating hormone (TSH). In this short review using two clinical
vignettes, we examine the diagnostic approach in such cases. A diagnostic algorithm is proposed to ensure that a definitive
diagnosis is reached in these challenging cases.
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Abbreviations
TSH Thyroid-stimulating hormone
fT4 Free thyroxine
anti-TPO Anti thyroid peroxidase antibodies
TR abs Thyroid receptor antibodies
FDH Familial dysalbuminemic hyperthyroxinemia
RTH Resistance to thyroid hormone
TRβ Thyroid hormone receptor beta.
Learning point 1
In a patient who is clinically euthyroid with elevated fT4 and
an inappropriately normal or raised TSH, the most likely cause
is assay interference. Interference should firstly be excluded
before considering rarer conditions such as resistance to thy-
roid hormone and TSHoma.
Learning point 2
Repeat thyroid function tests should be sent to another labo-
ratory using a different assay to unmask assay interference if
this is suspected.
Learning point 3
Focused drug history and family history of thyroid func-
tion abnormalities should be specifically sought in these
patients.
Learning point 4
When assay interference has been excluded, consider-
ation should be given to resistance to thyroid hormone
(RTH) and TSH-secreting pituitary adenoma (TSHoma).
Biochemical, dynamic testing, and imaging can be used
to differentiate between the two conditions. An algorith-
mic approach to investigation as herein presented en-
sures that a diagnosis is reached in this clinical
conundrum.
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Vignette 1
A 41-year old female was referred to the endocrinology clinic
with an elevated free T4 and a non-suppressed TSH. She had
initially presented to her general practitioner with lethargy.
Her GP performed routine blood tests, including thyroid func-
tion tests (TFTs), which revealed normal thyroid-stimulating
hormone (TSH) 0.82 mU/l (normal range 0.3–4.0 mU/l), but
raised free thyroxine (fT4) 30 pmol/l (normal range 13–
23 pmol/l). Total triiodothyronine (T3) was 1.3 nmol/l (normal
range 1.3–3.1 nmol/l). Other biochemistry laboratory tests in-
cluding renal function, liver function, plasma glucose, and
lipids were normal. On specific questioning, she reported a
vague history of heat intolerance and thin hair, but there were
no other specific symptoms to suggest thyrotoxicosis. There
was no history of menstrual irregularity, she was not taking
any regular medications, and there was no personal or family
history of thyroid disease. She was clinically euthyroid and
the thyroid gland was unremarkable on examination. Repeat
TFTs showed a similar pattern with normal range TSH and
raised fT4. Antithyroid peroxidase (anti-TPO) and TSH recep-
tor (TRAb) antibodies were not detected.
The vague symptoms this patient presents with may or may
not be attributed to thyroid disease. In the general population,
the commonest cause of this pattern of TFTs is irregular com-
pliance with prescribed levothyroxine in a patient who has
established hypothyroidism. TFTs repeated at the outpatient
clinic—using the same assay—produced a similar result.
Given that assay interference is well documented, a further
sample was sent to a different laboratory using a different
TFT assay with subsequently normal results. The patient was
reassured that the abnormal results were due to assay interfer-
ence. There was no clinical need for drug therapy or further
investigation and she was discharged from the clinic.
We now explore the common causes for spurious thyroid
function test results similar to those described in Vignette 1.
Assay interference
Assay interference in thyroid function testing has been esti-
mated as occurring in up to 1% of all tests performed. Given
the widespread testing of thyroid function in clinical practice,
assay interference is an important consideration [1]. The issue
of assay interference arises because there are several different
methods used to measure TSH, total and free thyroxine (T4),
and total and free triiodothyronine (T3), including radioimmu-
noassay, immunometric assay, and tandemmass spectrometry,
but differences in sensitivity, specificity, and standardization
can result in significant variability between these methods.
Different manufacturers use differing methods for measure-
ment. The gold standard free T4 assay is one that uses the
equilibrium dialysis method although this is not widely avail-
able [1, 2]. The fT4 assay platforms in routine use are not
always robust and can be affected by serum antibodies. The
commonest cause of a falsely high TSH is assay interference
from human anti-murine antibodies (HAMA) or thyroid hor-
mone autoantibodies (THAAbs) [1, 2]. Rheumatoid factor
(RF) is an antibody directed against human IgG and is often
present in people with autoimmune disease—particularly
rheumatoid arthritis. This can also interfere with TFT assays
and should be considered if the clinical picture is suggestive
[1]. Other antibodies such as anti-streptavidin and anti-
ruthenium antibodies can also cause assay interference [1].
Biotin is used with increasing frequency as a health supple-
ment and can interfere with certain TFT assays: this should be
considered in the clinical history [3, 4]. Since some analytical
methods are more susceptible to the effects of assay interfer-
ence than others, this issue can generally be identified by
remeasuring both TSH and fT4 using a different manufac-
turer’s assay platform [2]. In practice, this will usually involve
sending samples to another lab with a different TFT assay. In
practical terms, if a practitioner is unsure about the logistics of
this, the local clinical biochemist would be helpful in the or-
ganizational aspects of redirecting a sample for an alternative
assay measurement. If when using a different analytical meth-
od, the TFTs are normal, it suggests that assay interference is
the underlying problem and the patient can be reassured [5].
Drugs
Having considered assay interference as a spurious cause for
inappropriately non-suppressed TSHwith high normal or high
fT4, we now consider drug causes which should be specifi-
cally sought in patients presenting with such biochemistry.
Several drugs are known to cause discordant TFTs similar to
those presented in vignette 1. As already alluded to,
levothyroxine if taken irregularly mostly results in a raised
TSH with normal free T4 levels; however, if erratic or inap-
propriate doses of thyroxine are taken, the free T4 can also be
high. Aside from the overt effects of amiodarone on the thy-
roid gland itself, amiodarone also inhibits extrathyroidal con-
version of T4 to T3 as can glucocorticoids and propranolol
also. This results in a reduced T3, increase in reverse T3 (rT3),
and raised T4 (although this can also be normal) with a non-
suppressed TSH. Heparin displaces T4 from thyroid-binding
globulin (TBG), resulting in an apparently inappropriately
high free T4 on TFTs [5].
Genetic causes
Changes affecting one of the thyroid hormone binding pro-
teins, such as thyroid binding globulin (TBG), transthyretin,
or albumin, can also affect the free T4 assay as is the case in
familial dysalbuminemic hyperthyroxinemia (FDH). This is a
rare genetic condition in which albumin has a preferential
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affinity for T4, which can lead to alterations in total and free
T4 levels with non-suppressed TSH [2, 5, 6].
Vignette 2
A 39-year old woman was referred to our clinic having
attended her GP with back pain, abdominal discomfort, and
bloating. She was incidentally found to have abnormal thyroid
function tests. Biochemistry revealed a TSH of 1.66 mU/l
(0.3–4.0 mU/l), free T4 45 pmol/l (13–23 pmol/l), and total
T3 3.2 nmol/l (1.3–3.1 nmol/l). When reviewed in the clinic,
she was tachycardic (heart rate 120/min regular) and was
found to have a small, uniform goiter. No other abnormalities
were found. TFTs were firstly repeated using a different assay
and results were similar. Thyroid autoantibodies were not de-
tected. Renal function, liver function, plasma glucose, and
lipids were normal. There was no family history of thyroid
disease.
In this case, the patient has some objective features
of thyrotoxicosis, notably a resting tachycardia. Since
repeat TFTs using a different assay still demonstrated
a discordant pattern with raised fT4 and inappropriately
normal TSH, the patient was offered further endocrine
investigation. (Fig. 1).
In this clinical context having excluded any obvious
spurious cause for TFT derangement, two rare condi-
tions must be considered: TSH-secreting pituitary ade-
noma (TSHoma) and resistance to thyroid hormone
(RTH) with loss of function in the thyroid hormone
receptor beta gene (TRβ). The differentiation between
these conditions is often difficult.
TSH-secreting pituitary adenoma
TSH-secreting pituitary adenoma (TSHoma) is a rare condi-
tion with a prevalence of approximately one per million [7, 8].
They are the least common form of functional pituitary ade-
noma accounting for only around 2% of all pituitary tumors
diagnosed [7, 8]. The incidence of TSHoma has increased,
likely due to improvements in biochemical and imaging mo-
dalities allowing more accurate diagnosis [9–12]. While these
tumors are almost invariably benign, they are often large in-
vasive fibrous tumors at the time of resection. A total of 90%
are macroadenomas, and as such may cause local mass effect
and headache. The majority (approximately two-thirds) dem-
onstrate invasion into local structures at the time of diagnosis.
While between 70 and 80% of these tumors secrete only TSH,
approximately 25% are mixed and co-secrete growth hormone
or prolactin [9–12]. In such cases, hypersecretion of these
other anterior pituitary hormones may dominate the clinical
picture. Patients generally present however with typical symp-
toms of thyrotoxicosis. There is often a goiter on examination.
Visual field defects should be sought and formal visual field
testing should be undertaken given the propensity of these
tumors to be large and locally invasive at diagnosis.
Hypogonadotrophic hypogonadismmay also rarely be present
and in females, oligomenorrhea or amenorrheamay be present
[5, 8, 9].
The treatment of choice is transphenoidal resection of the
pituitary adenoma following pituitary multidisciplinary team
discussion. If surgery is contraindicated or declined, pituitary
radiotherapy and medical treatment with somatostatin analogs
can be used to suppress TSH secretion in 80% of TSHomas
[7–12].
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Resistance to thyroid hormone
Resistance to thyroid hormone (RTH) is the second condition
which must be considered when presented with this pattern of
TFTs. RTH was first described in 1967 and is estimated to
occur in around 1/40,000 to 1/50,000 live births [5]. In around
80% of cases, the mutation is inherited in an autosomal dom-
inant fashion. The remainder of cases are due to a de novo
mutation. It is primarily an inherited syndrome of reduced
end-organ sensitivity to thyroid hormone which specifically
pertains to defects of the thyroid hormone receptor [13]. This
results in reduced intracellular action of the active thyroid
hormone T3. The resistance to thyroid hormone can either
be general (GRTH) or selective pituitary resistance to thyroid
hormone (PRTH) [13, 14]. This can alter the clinical manifes-
tation: if the pituitary is predominantly resistant but the pe-
ripheral tissues are not, patients may present with clinical fea-
tures of thyrotoxicosis. The majority (around 85%) of patients
with RTH have mutations in the thyroid hormone receptor β
(TRß) gene, resulting in dysfunctional beta receptors, which
have also been found to diminish the activity of normal recep-
tors, explaining the unresponsiveness of end-organ tissues to
thyroid hormone [14]. Clinical manifestations are heteroge-
neous, but with the exception of goiter are often absent.
When present, clinical signs may include coexistent paradox-
ical signs of thyroid underactivity and overactivity, including
goiter (the most common finding), hyperactivity, learning dis-
abilities, growth delay, and resting tachycardia. A number of
people with RTH however may be relatively asymptomatic or
present with mild symptoms and therefore diagnosis is fre-
quently made in adulthood following incidental thyroid func-
tion testing or investigation of tachyarrythmia [5, 13, 14].
Treatment is generally not required for RTH although may
be required symptomatically in selective pituitary resistance to
thyroid hormone. Beta blockers can be used to treat thyrotoxic
symptoms [5, 13, 14].
Given the heterogeneity and overlap in the clinical manifes-
tations of both of these conditions, it is not possible to distin-
guish between RTH and a TSH-secreting pituitary adenoma
from clinical history or examination alone. Similarly, the
TSH and fT4 levels can often overlap between RTH and
TSH-producing pituitary adenoma; therefore, biochemistry
cannot reliably be used to differentiate between the two condi-
tions either. TSH may be within normal range or elevated in
TSHoma and in RTH. Arguably, the best biochemical investi-
gation in the initial differentiation of TSHoma and RTH is
serum glycoprotein alpha subunit (α-GSU). Alpha subunit is
high in about 70%of patients with TSHoma. It is ordinarily not
elevated in RTH; however, in approximately 1 in 20 patients
with selective pituitary RTH, it can be elevated. Alpha subunit
elevation is due to an unbalanced hypersecretion of alpha sub-
unit in TSHoma. This is particularly true in macroadenomas
which account for the majority of such tumors [5].
The TRH (thyrotropin-releasing hormone) stimulation test
is useful in differentiating between TSHoma and RTH. Two
hundred micrograms of TRH is given intravenously with sam-
pling at 0, 20, and 60 min. A normal or exaggerated response
to TRH is typically seen in RTH with a peak TSH of greater
than fivefold baseline. This can be used to complement sub-
sequent genetic studies if this diagnosis is suspected.
Conversely, in TSHoma, an attenuated or absent TSH re-
sponse is seen, but with generally less than a 1.5-fold rise in
TSH from baseline in macroadenomas, although a greater
response may paradoxically be seen with microadenomas
[7–12].
Although not used in this case, T3 suppression testing can
also be used to differentiate between TSHoma and RTH. A
total of 80 to 100 μg per day is given in three divided doses
over a 10-day period with beta-blockers. TSH sampling at day
0, day 5, and day 10 is undertaken. In TSHoma, TSH suppres-
sion is typically not seen despite T3 administration, while in
RTH (both PRTH and GRTH) suppression of TSH typically
occurs. Another mechanism for differentiating the two condi-
tions is octreotide suppression testing. Octreotide (long-acting
release) is administered at a dose of 20mg per month over a 2-
month period. In approximately 95% of people with TSH-
secreting pituitary adenoma, a fall in TSH is seen with this
regimen. There is no fall in TSH in resistance to thyroid hor-
mone [7, 12].
Imaging of the pituitary gland with MRI scanning should
be considered if initial biochemical findings suggest TSHoma.
Imaging will typically demonstrate a macroadenoma, which
accounts for 80% of TSHomas. Given the propensity for
macroadenoma, formal perimetry testing should be conduct-
ed. A small proportion of these tumors are microadenomas
and rarely ectopic TSH-secreting tumors have been described.
The possibility of an incidental pituitary adenoma in the con-
text of RTH may further confound diagnosis given the preva-
lence of this in the general population; therefore, care must be
taken to ensure that a correct diagnosis is reached on the basis
of biochemistry, dynamic testing, genetic analysis, and imag-
ing [5, 7, 13, 14].
In this patient, the algorithmic approach presented (Fig. 1)
was used to reach a definitive diagnosis of RTH. ATRH test
was performed. This demonstrated a normal pituitary response
to TRH stimulation (Table 1). Alpha subunit measurement
was within the normal range at 1.9 IU/l (< 3.0 IU/l). This
was consistent with a diagnosis of resistance to thyroid hor-
mone. RTH was subsequently confirmed by genetic testing
(fluorescent sequencing analysis of exon 9), which showed
thyroid hormone receptor beta (TRß) mutation. This causes
predominant pituitary resistance to thyroid hormone as op-
posed to generalized resistance [13, 14].
The diagnosis and consequences of thyroid hormone resis-
tance was explained to the patient, and genetic counseling
offered. Genetic testing for her siblings was refused. Given
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the autosomal dominant nature of this condition, the presence
of similar biochemical phenotype in first degree relatives is
highly suggestive of RTH and family screening should be
offered.
Conclusion
In both cases, fT4 is elevated and TSH is inappropriately non-
suppressed. Since assays can have variable performance, a
logical approach needs to be taken when TSH levels are
non-suppressed in the presence of elevated free T4 levels.
We propose an algorithm (Fig. 1) for the management of such
discordant thyroid function tests accompanied by two practi-
cal clinical examples to illustrate its use in practice. When
there is raised fT4 with an inappropriately normal or raised
TSH, firstly exclude assay interference before considering
further investigation as per our proposed algorithm.
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Table 1 Vignette 2 TRH test results
Time (min) TSH (mU/l) fT4 (pmol/l)
0 1.47 47
20 14.17 44
60 8.81 51
TRH (thyrotropin-releasing hormone) stimulation test for the patient in
vignette 2. Two hundred micrograms of TRH is administered intrave-
nously. TSH levels are then measured at 0, 20, and 60 min. The greater
than fivefold increase in TSH is highly suggestive of resistance to thyroid
hormone. In TSHoma, an attenuated or absent response is seen (generally
no greater than 1.5-fold increase in TSH)
Hormones
